Exosomes News and Research

RSS

StemCells granted UK patent covering true rat stem cells and genetically engineered rats

StemCells, Inc. announced today that the United Kingdom (UK) Intellectual Property Office has granted patent number GB2451523 with broad claims covering true (germline competent) rat stem cells and genetically engineered rats derived from these cells. The patented technology is expected to have significant utility to academic and pharmaceutical industry researchers by enabling them to create novel rat models for the study of human diseases. Both mice and rats are used by scientists to model various human diseases.

18 Mar 2010

Avid Bioservices highlights data of single-use bioreactors and traditional stainless steel bioreactors

Avid Bioservices, Inc. today presented data highlighting the comparability of production run performance between the company's single-use bioreactors (Thermo Scientific HyClone S.U.B.) and its traditional stainless steel bioreactors at the Thermo Scientific BioProduction Optimization Workshop in San Francisco, California.

From Thermo Fisher Scientific Inc. 17 Mar 2010

BeaconEquity.com: STEM losses $5.2M in fourth-quarter of 2009

BeaconEquity.com announces an investment report featuring biotech company StemCells Inc. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

16 Mar 2010

Researchers gain new understanding of cilial protein Arl13b in Joubert syndrome

Researchers in Ireland have gained new understanding of the role played by the cilial protein Arl13b in Joubert syndrome (JS), a rare disorder characterized by developmental delay, mental retardation, and low muscle tone, among other symptoms.

16 Mar 2010

New method to better study prostate cancer

Van Andel Research Institute researchers have developed a new method to better study the cells that line and protect the prostate in relation to the development of cancer. Using the model, they found that normal cells and cancer cells depend on different factors to survive, which could aid in discovering how to target cancer cells without affecting normal cells when developing treatments.

12 Mar 2010

Baxter International, DVC present Phase III clinical efficacy data for PREFLUCEL

Baxter International Inc., in conjunction with DynPort Vaccine Company LLC, a CSC Company, today presented Phase III study data measuring the clinical efficacy for PREFLUCEL, a trivalent seasonal influenza candidate vaccine. PREFLUCEL is made using Baxter’s Vero cell culture platform and does not contain an adjuvant or preservatives. The data were presented at the International Congress on Infectious Disease (ICID) in Miami, Florida.

From Baxter International Inc. 12 Mar 2010

Peregrine Pharmaceuticals' third-quarter fiscal 2010 total revenues up 45%

Peregrine Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and serious viral infections, today announced financial results for the third quarter of fiscal year (FY) 2010 ended January 31, 2010. The company also provided an update on its clinical programs and corporate developments.

From Thermo Fisher Scientific Inc. 11 Mar 2010

StemCells reports net loss of $5.23M for fourth-quarter fiscal 2009

StemCells, Inc. today reported financial results for the fourth quarter and year ended December 31, 2009. The Company's results include the operations of Stem Cell Sciences Plc (SCS) since April 1, 2009.

11 Mar 2010

Lonza acquires access to PCA technology patent portfolio

Odyssey Thera, Inc., announced today the signing of an agreement with Lonza to make Odyssey Thera's proprietary Protein-fragment Complementation Assay (PCA) technology, as part of compound profiling services, available to life science and drug discovery researchers.

10 Mar 2010

Growing human therapeutic proteins in algae can help reduce cancer treatment cost

Pharmaceutical companies could substantially reduce the expense of costly treatments for cancer and other diseases produced from mammalian or bacterial cells by growing these human therapeutic proteins in algae-rapidly growing aquatic plant cells that have recently gained attention for their ability to produce biofuels.

9 Mar 2010

Corning Lab for Cure program

Corning Incorporated today announced the Corning Lab for the Cure™ program, a first-of-its-kind corporate sponsorship agreement with Susan G. Komen for the Cure®.

9 Mar 2010

Thymosin beta 4 improves neurological functional outcome

REGENERX BIOPHARMACEUTICALS, INC. announced that a research team from the Henry Ford Hospital in Detroit, MI reported that Thymosin beta 4 (Tβ4), administered to rats one day after embolic stroke, improved neurological functional outcome compared to control animals.

6 Mar 2010

SCLL signs agreement to provide research and assay services in support of Agennix's talactoferrin program

Stem Cell Innovations announced today that the Company has signed a Master Services Agreement to provide research and assay services in support of Agennix's talactoferrin program. The assay utilizes SCLL's C3A human liver cell line.

3 Mar 2010

Sigma-Aldrich unveils new Sigma Life Science brand and website platform

Sigma-Aldrich® today unveiled its new Sigma® Life Science brand and website platform, designed to elevate the Company's current focus on biology and provide a single destination where researchers can access deep biological knowledge and market-leading products and technologies.

2 Mar 2010

Transplanting genetically modified adult stem cells into injured spinal cord increases movement recovery

Researchers at UTHealth have demonstrated in rats that transplanting genetically modified adult stem cells into an injured spinal cord can help restore the electrical pathways associated with movement. The results are published in the Feb. 24 issue of the Journal of Neuroscience.

25 Feb 2010

Quidel acquires Diagnostic Hybrids for $130 million

Quidel Corporation, a leading provider of rapid diagnostic tests, has completed its previously announced acquisition of Diagnostic Hybrids, Inc. for approximately $130 million in cash.

20 Feb 2010

International Stem Cell's human cornea technology: Clinical-commercial opportunities in Asia and Europe

International Stem Cell Corporation, announced today that multiple international meetings taking place between ISCO’s executive management and researchers and clinicians from commercial entities in both Asia and Europe revealed significant clinical-commercial opportunities for the company’s stem cell-derived human cornea technology in those regions.

17 Feb 2010

BAC adds affinity resin for AAT purification to GE Healthcare’s range of custom designed media

BAC BV, the leading provider of antibody-based affinity purification technology, has extended its collaboration with GE Healthcare with the addition of a new bioprocess affinity chromatography ligand to GE Healthcare’s range of custom designed media. The latest addition to the range is an affinity resin for the purification of alpha-1 antitrypsin (AAT) from blood plasma, recombinant cell culture or transgenic sources. The new resin has been developed as part of GE Healthcare’s Custom Designed Media (CDM) programme and provides a new solution for AAT purification in the biopharmaceutical industry.

17 Feb 2010

NanoViricides signs research and development agreement with Dr. Eva Harris’s laboratory at UC Berkeley

NanoViricides, Inc. (the "Company"), reports that it has signed a research and development agreement with Dr. Eva Harris’s laboratory at the University of California, Berkeley (UC Berkeley).

17 Feb 2010

Neurotoxin study may help find new therapies to block hyperactive ion channels

There are approximately 500 species of cone snails, each producing 50 - 200 different conotoxins. A similar number of peptide toxins are produced by snakes, spiders, sea anemones, scorpions and other venomous animals. The animals use the neurotoxins to paralyze their prey.

11 Feb 2010

Exosomes News and Research

StemCells granted UK patent covering true rat stem cells and genetically engineered rats

Avid Bioservices highlights data of single-use bioreactors and traditional stainless steel bioreactors

BeaconEquity.com: STEM losses $5.2M in fourth-quarter of 2009

Researchers gain new understanding of cilial protein Arl13b in Joubert syndrome

New method to better study prostate cancer

Baxter International, DVC present Phase III clinical efficacy data for PREFLUCEL

Peregrine Pharmaceuticals' third-quarter fiscal 2010 total revenues up 45%

StemCells reports net loss of $5.23M for fourth-quarter fiscal 2009

Lonza acquires access to PCA technology patent portfolio

Growing human therapeutic proteins in algae can help reduce cancer treatment cost

Corning Lab for Cure program

Thymosin beta 4 improves neurological functional outcome

SCLL signs agreement to provide research and assay services in support of Agennix's talactoferrin program

Sigma-Aldrich unveils new Sigma Life Science brand and website platform

Transplanting genetically modified adult stem cells into injured spinal cord increases movement recovery

Quidel acquires Diagnostic Hybrids for $130 million

International Stem Cell's human cornea technology: Clinical-commercial opportunities in Asia and Europe

BAC adds affinity resin for AAT purification to GE Healthcare’s range of custom designed media

NanoViricides signs research and development agreement with Dr. Eva Harris’s laboratory at UC Berkeley

Neurotoxin study may help find new therapies to block hyperactive ion channels

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest Life Science News